TY - JOUR
T1 - Diclectin therapy for nausea and vomiting of pregnancy
T2 - effects of optimal dosing.
AU - Boskovic, Rada
AU - Einarson, Adrienne
AU - Maltepe, Caroline
AU - Wolpin, Jacob
AU - Koren, Gideon
N1 - Funding Information:
The Motherisk NVP Healthline is supported by Duchesnay Inc. Laval, Canada, manufacturers of Diclectin.
Funding Information:
Nausea and vomiting of pregnancy, Diclectin, pyridoxine hydrochloride, doxylamine This study was supported by grants from the Canadian Institutes of Health Research and the Research Leadership for Pharmacotherapy During Pregnancy and Lactation.
Funding Information:
Dr Koren is a Senior Scientist of the Canadian Institutes of Health Research. Dr Boskovic was supported by a Fellowship from the Canadian Society for Clinical Pharmacology.
PY - 2003/10
Y1 - 2003/10
N2 - OBJECTIVES: (1) To quantify rates of suboptimal use of pyridoxine hydrochloride-doxylamine (Diclectin); and (2) to study responses to optimal doses of Diclectin in women previously taking a suboptimal dose. METHODS: Women who called the Motherisk NVP helpline, and were taking only Diclectin (vitamin B6 10 mg and doxylamine 10 mg), were enrolled in the study and assessed for the severity of nausea and vomiting of pregnancy (NVP) with the Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system. Their Diclectin doses were subsequently increased according to body weight and individual symptoms. A follow-up phone call occurred within 1 to 3 weeks after the intervention, at which time the overall PUQE score was repeated, along with individual scoring of symptoms of nausea, vomiting, and retching. RESULTS: Sixty-eight women were enrolled and completed the study. Despite moderate to severe NVP, defined by the validated PUQE scoring system, most women (50/68) were receiving 2 tablets a day of Diclectin instead of the recommended dose of 4 tablets a day. Following a mean doubling of the dose to 4 tablets a day, there was a significant decrease in length of nausea (from 4 to 3 hours, P < 0.001), frequency of vomiting (from mean 1.6 to 1.3 a day, P = 0.02), and overall PUQE score (from mean 7.5 to 6.1, P < 0.001). CONCLUSION: Women suffering from NVP are often given subtherapeutic doses of Diclectin. Women should receive a dosage according to their body weight and severity of their symptoms.
AB - OBJECTIVES: (1) To quantify rates of suboptimal use of pyridoxine hydrochloride-doxylamine (Diclectin); and (2) to study responses to optimal doses of Diclectin in women previously taking a suboptimal dose. METHODS: Women who called the Motherisk NVP helpline, and were taking only Diclectin (vitamin B6 10 mg and doxylamine 10 mg), were enrolled in the study and assessed for the severity of nausea and vomiting of pregnancy (NVP) with the Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system. Their Diclectin doses were subsequently increased according to body weight and individual symptoms. A follow-up phone call occurred within 1 to 3 weeks after the intervention, at which time the overall PUQE score was repeated, along with individual scoring of symptoms of nausea, vomiting, and retching. RESULTS: Sixty-eight women were enrolled and completed the study. Despite moderate to severe NVP, defined by the validated PUQE scoring system, most women (50/68) were receiving 2 tablets a day of Diclectin instead of the recommended dose of 4 tablets a day. Following a mean doubling of the dose to 4 tablets a day, there was a significant decrease in length of nausea (from 4 to 3 hours, P < 0.001), frequency of vomiting (from mean 1.6 to 1.3 a day, P = 0.02), and overall PUQE score (from mean 7.5 to 6.1, P < 0.001). CONCLUSION: Women suffering from NVP are often given subtherapeutic doses of Diclectin. Women should receive a dosage according to their body weight and severity of their symptoms.
UR - http://www.scopus.com/inward/record.url?scp=1542568280&partnerID=8YFLogxK
U2 - 10.1016/S1701-2163(16)30673-9
DO - 10.1016/S1701-2163(16)30673-9
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 14532951
AN - SCOPUS:1542568280
SN - 1701-2163
VL - 25
SP - 830
EP - 833
JO - Journal of Obstetrics and Gynaecology Canada
JF - Journal of Obstetrics and Gynaecology Canada
IS - 10
ER -